Navigation Links
Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/16/2010

of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing its biologic effects.  Anivamersen is the active control agent of pegnivacogin.  

More information can be found at www.regadobio.com.Contact:Ellen McDonaldChief Business OfficerRegado Biosciences1-908-580-2113emcdonald@regadobio.comMedia Contact:Tiberend Strategic Advisors, Inc.1-212-827-0020Andrew Mielachamielach@tiberendstrategicadvisors.com
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
3. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
6. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
10. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
11. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Cepheid (Nasdaq: CPHD ... update to Xpert® Carba-R, with the addition of ... The on-demand, molecular test also detects and differentiates ... resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48. ... CROs or Superbugs, are a growing and expensive ...
(Date:7/29/2015)... MOUNTAIN VIEW, Calif. , July 29, 2015 /PRNewswire/ ... in the growth strategy of pharmaceutical firms in ... . The realization is that an effective working ... sales, pricing pressures and patent cliffs. Big pharma companies ... bolster returns. Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO ...
(Date:7/29/2015)... , July 29, 2015 ... Therapeutic Vaccines Market - Growth, Trends & Forecasts (2015-2020) ... expected to be worth US$ 2.85 billion by the ... being the largest market globally accounting for more ... market for Therapeutic Vaccines is expected to grow at ...
Breaking Medicine Technology:'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 2New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 3
... Leader Ventures, an investment firm offering blended debt and ... Inc., an innovative drug discovery company. ... co-founders Stig K. Hansen and Daniel A. Erlanson while ... candidates in a broad range of therapeutic areas. ...
... 20, 2010 Valeant Pharmaceuticals International, Inc. (NYSE: ... W. Loberg, Valeant,s former senior vice president and corporate ... chief financial officer, effective immediately, replacing Peggy Mulligan, former ... order to pursue other interests.  The Company has initiated ...
Cached Medicine Technology:Leader Ventures Supports Innovative Drug Discovery Company Carmot 2Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 2Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 3
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... a decision from the Judicial Panel on Multidistrict Litigation (JPML), according to court ... defects research at their website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, ...
(Date:7/29/2015)... ... July 29, 2015 , ... " mybody ” was featured ... small, medium and large businesses making an impact in their industry. Andrew Tropeano, the ... how these advanced probiotic skincare products are designed to strengthen the skin’s defense system ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... it has entered into a partnership with 247Ergo, an ergonomics specialty firm. Purpose ... wellness. Ergonomics projects that the companies undertake could improve worker mobility, functionality and ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... illnesses is seeking funding for a study on the potentially lifesaving impact of ... Institute today . , The research proposal is based on a successful ...
(Date:7/29/2015)... Rosa, CA (PRWEB) , ... July 29, 2015 , ... ... hernias have advanced as a result. Information provided by the National Center for ... – and three million new cases are reported annually. While the only effective ...
Breaking Medicine News(10 mins):Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Strengthen the Skin’s Defense System from the Inside Out with mybody 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 3Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 2Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 3
... chronic myeloid leukemia patients who are out of treatment options ... their cancer cells have a mutation that makes them resistant ... of the American Society of Hematology. In a Phase ... hematologic responses (absence of CML cells in the blood) and ...
... inhibitors are substantially improving treatment of myelofibrosis ( ... http://www.mayoclinic.org/ ) researchers who are presenting results of ... of the American Society of Hematology ( http://www.hematology.org/ ... VIDEO ALERT: Additional audio and video resources, including ...
... Texas AgriLife Research engineers has developed a way to cut ... to kill 99.999 percent of salmonella, E. coli ... in a Mylar bag filled with pure oxygen, Dr. Carmen ... they could significantly reduce the amount of radiation needed to ...
... HealthDay Reporter , SUNDAY, Dec. 5 (HealthDay ... they managed to "correct" a malfunctioning gene responsible for ... leads to prolonged bleeding from even minor hits or ... cancers and dangerous infections. However, one of the ...
... Reporter , SATURDAY, Dec. 4 (HealthDay News) -- A new ... safer treatment for patients coping with deep-vein thrombosis (DVT), a ... published online Dec. 4 in the New England Journal ... for these potentially life-threatening clots, which most typically form ...
... Quigley will describe a promising new approach to blocking ... meeting in Orlando, Fla. Quigley will speak at ... at the Orange County Convention Center, 9800 International Drive, ... the Human Erythroid Heme Exporter, FLVCR, Export Heme: Potential ...
Cached Medicine News:Health News:Phase I trial indicates ponatinib may thwart most resistant CML 2Health News:JAK inhibitors producing significant response in myelofibrosis patients 2Health News:JAK inhibitors producing significant response in myelofibrosis patients 3Health News:AgriLife researchers find way to cut food-irradiation levels by half 2Health News:AgriLife researchers find way to cut food-irradiation levels by half 3Health News:AgriLife researchers find way to cut food-irradiation levels by half 4Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 2Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 3Health News:New Blood Thinner May Help Fight Dangerous Leg Clots 2Health News:New Blood Thinner May Help Fight Dangerous Leg Clots 3Health News:UIC researcher unveils new approach to blocking malaria transmission 2
Designed to minimize emblolic debris in SVGs and carotids...
... The dual lumen titanium ... 1.2 mm inner diameter ... oval lumen catheters offer ... maintaining maximum catheter strength. ...
The standard-sized titanium port may be ordered with a silicone or polyurethane catheter. The silicone catheter is available with inner diameter sizes of 0.9, 1.0, 1.4, 1.6 mm. The polyurethane cathe...
... The Statscan Critical Imaging System is ... aimed specifically at the needs of emergency ... the radiography needs of both trauma patients ... life-saving information to the medical staff by ...
Medicine Products: